Hyperliquid Strategies FCF/Debt

What does Hyperliquid Strategies do? Hyperliquid Strategies Inc, trading under the ticker PURR with ISIN US44916Y1064, is a US-based company headquartered in New York City. The company operates within the Health Care sector, specifically in the Biotechnology industry. Hyperliquid Strategies Inc. made its initial public offering (IPO) on December 3, 2025. The company is described as a digital asset treasury company, focusing on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain designed to support financial applications. The company also has a subsidiary, Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology firm. Sonnet BioTherapeutics operates with a proprietary platform for developing biologic drugs, including single and bifunctional action drugs. The company's primary focus is on the accumulation of HYPE, the native token of the Hyperliquid blockchain, which is positioned as a high-performance blockchain for financial applications. Hyperliquid Strategies Inc. does not provide further details on its operations, financial figures, or specific product names beyond the information provided. The company's structure includes a subsidiary dedicated to oncology research and drug development, emphasizing its dual focus on digital assets and biotechnology. Hyperliquid Strategies is one of the most popular companies on Eulerpool.